Role of HIF1A gene polymorphisms with serum uric acid and HIF-1α levels in monosodium urate crystal-induced arthritis
- PMID: 39256280
- DOI: 10.1007/s10067-024-07129-6
Role of HIF1A gene polymorphisms with serum uric acid and HIF-1α levels in monosodium urate crystal-induced arthritis
Abstract
Background: Gouty arthritis is a metabolic disease characterized by the deposition of monosodium urate crystals in the joints, which triggers the release of interleukin-1β (IL-β) by activating the NLRP3 inflammasome. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor involved in IL-β production and as a regulator of NLRP3.
Objectives: The aims were to analyze the association of HIF1A rs11549465, rs11549467, and rs2057482 variants in patients with gouty arthritis, and to evaluate the correlation between urate and HIF-1α levels according to the associated genotypes.
Methods: Cases and controls were genotyped using TaqMan probes, and urate and HIF-1α levels were quantified. Data were analyzed using SPSS v21 software and P-values < 0.05 were considered statistically significant.
Results: Urate and HIF-1α levels were higher in patients than in controls (P < 0.05). Under the three inheritance models (codominant, dominant, and recessive), the AA genotype of the rs11549467 variant was associated with gout risk (OR = 5.74, P = 0.009, OR = 3.33, P = 0.024, and OR = 9.09, P = 0.003, respectively). There were significant differences in the distribution of serum levels of both HIF-1α (P < 0.0001) and urate (P = 0.016) according to the genotypes of the rs11549467 variant.
Conclusion: These results suggest that the HIF1A rs11549467 variant may play a key role in the pathogenesis of gouty arthritis. Key Points • The pathogenesis of gouty arthritis involves the HIF1A gene. • In patients with gout, the AA genotype of the rs11549467 (HIF1A) variant is associated with increased serum levels of urate and HIF-1α. • HIF-1α is involved in the regulation of IL-1β and NLRP3.
Keywords: HIF1A gene; Genetic polymorphisms; Gouty arthritis; Hypoxia inducible factor-1α; Urate.
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Similar articles
-
Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis.Rheumatology (Oxford). 2017 Mar 1;56(3):457-466. doi: 10.1093/rheumatology/kew337. Rheumatology (Oxford). 2017. PMID: 28394398
-
Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population.Asian J Androl. 2012 Nov;14(6):864-9. doi: 10.1038/aja.2012.101. Epub 2012 Oct 8. Asian J Androl. 2012. PMID: 23042446 Free PMC article.
-
The association of genetic polymorphisms of hypoxia inducible factor-1 alpha and vascular endothelial growth factor with increased risk of chronic obstructive pulmonary disease: A case-control study.Kaohsiung J Med Sci. 2017 Sep;33(9):433-441. doi: 10.1016/j.kjms.2017.05.014. Epub 2017 Jul 5. Kaohsiung J Med Sci. 2017. PMID: 28865600 Free PMC article.
-
Association of Hypoxia-Inducible Factor 1α Gene Polymorphisms With Breast Cancer Susceptibility: A Meta-Analysis.JCO Glob Oncol. 2022 Mar;8:e2100399. doi: 10.1200/GO.21.00399. JCO Glob Oncol. 2022. PMID: 35507894 Free PMC article.
-
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.Immunol Invest. 2023 Apr;52(3):364-397. doi: 10.1080/08820139.2023.2168554. Epub 2023 Feb 6. Immunol Invest. 2023. PMID: 36745138 Review.
References
-
- Sivera F, Andres M, Dalbeth N (2022) A glance into the future of gout. Ther Adv Musculoskelet Dis 14:1759720X221114098. https://doi.org/10.1177/1759720X221114098 - DOI - PubMed - PMC
-
- Lee JH, Kim HS, Lee JH, Yang G, Kim HJ (2022) Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout. Front Pharmacol 13:861399. https://doi.org/10.3389/fphar.2022.861399 - DOI - PubMed - PMC
-
- Klück V, Jansen TLTA, Janssen M, Comarniceanu A, Efdé M, Tengesdal IW, Schraa K, Cleophas MCP, Scribner CL, Skouras DB, Marchetti C, Dinarello CA, Joosten LAB (2020) Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol 2:e270–e280. https://doi.org/10.1016/s2665-9913(20)30065-5 - DOI - PubMed - PMC
-
- Danve A, Sehra ST, Neogi T (2021) Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol 35:101723. https://doi.org/10.1016/j.berh.2021.101723 - DOI - PubMed - PMC
-
- Chaudhary K, Malhotra K, Sowers J, Aroor A (2013) Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med 3:208–220. https://doi.org/10.1159/000355405 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources